Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hyperion Therapeutics gets $60mm through its Series C

Executive Summary

Hyperion Therapeutics (developing GI and hepatic drug candidates) has raised $60mm through the closing of its Series C venture round. First-time investors Bay City Capital and Panorama Capital co-led and were joined by returning backers Highland Capital Partners, NEA, and Sofinnova Ventures. The company will use the money to study HPN100 in Phase III trials for chronic urea cycle disorders and Phase II for low-grade hepatic encephalopathy. Representatives from Bay City Capital and Panorama Capital will take seats on Hyperion's board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies